SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

Summit Therapeutics is currently trending as investors monitor ivonescimab's potential to disrupt the oncology market, with heavy focus on its head-to-head performance against Keytruda. The community is actively debating the company's future ahead of upcoming clinical data, balancing optimism about its transformative pipeline against concerns regarding competition and clinical trial timelines.

NXP Semiconductors NV is a holding company which engages in the provision of semiconductor solutions. It operates through the following geographical segments: China, Netherlands, United States, Singapore, Germany, Japan, South Korea, Malaysia, and Other Countries. The company was founded on August 2, 2006, and is headquartered in Eindhoven, the Netherlands.

NXP Semiconductors NV

NXP Semiconductors (NXPI) is trending as institutional investors rotate into automotive and industrial silicon plays following broad-market volatility and robust earnings reactions. The community is actively discussing the company's breakout potential as it positions itself as a critical player in AI-enabled automotive infrastructure and edge computing.

Vishay Precision Group, Inc. engages in the provision of precision measurement and sensing technologies. The firm serves a diverse array of industries and markets, including industrial, test and measurement, transportation, steel, medical, agriculture, avionics, military and space, and consumer. It operates through the following segments: Sensors, Weighing Solutions, Measurement Systems, and Corporate and Other. The Sensors segment is composed of the foil resistor and strain gage operating divisions. The Weighing Solutions segment consists of specialized modules and systems used to precisely measure weight, force torque, and pressure. The Measurement Systems segment includes specialized systems for steel production, materials development, and safety testing. The company was founded on August 28, 2009 and is headquartered in Malvern, PA.

Vishay Precision Group Inc

Vishay Precision Group is gaining significant traction as a key provider of precision sensors for humanoid robotics and physical AI infrastructure, with market participants closely monitoring its role in the supply chains of major robotics developers. Investors are particularly focused on the company's growth potential and its ability to capitalize on the accelerating shift toward automation as it becomes a strategic partner for high-profile technology firms.

Samsara, Inc. develops internet connected sensor systems. It combines plug-and-play sensors, wireless connectivity, and cloud-hosted software integrated for deployment. The company was founded by John Bicket and Sanjit Biswas in 2015 and is headquartered in San Francisco, CA.

Samsara Inc - Ordinary Shares - Class A

Samsara Inc

Samsara Inc. (IOT) is currently drawing significant investor interest as the market positions itself ahead of upcoming earnings, with high anticipation for another strong performance. Community discussion is focused on the stock's recent price action, potential breakouts above key resistance levels, and the company's long-term utility in the 'physical AI' and industrial IoT sectors.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Johnson & Johnson

Johnson & Johnson is currently in the spotlight as investors weigh strong fourth-quarter financial results and bullish 2026 growth guidance against ongoing concerns surrounding the impact of patent expirations and active talc litigation. Market conversation is particularly focused on the company's ability to drive its Innovative Medicine and MedTech segments to sustain long-term growth while managing significant legal liabilities.

Pulse Biosciences, Inc. operates as an immuno-oncology company developing a proprietary oncolytic electroceutical therapy based on its Nano Pulse Stimulation (NPS) technology. It manufactures surgical and medical instruments using a novel and proprietary platform technology called Nano-Pulse Electro-Signaling. The NPES provides local tumor control and initiates an adaptive immune response with a vaccine-like effect by inducing immunogenic apoptosis of the cells. The company was founded on May 19, 2014 and is headquartered in Miami, FL.

Pulse Biosciences Inc

Pulse Biosciences is trending as investors capitalize on clinical momentum, particularly regarding its nanosecond pulsed field ablation technology and positive data from cardiac and thyroid studies. The community is actively discussing the stock's long-term potential as a buyout candidate, while closely monitoring insider buying and leadership activity as indicators of future growth.

Payoneer Global, Inc. is a financial technology company, which engages in providing a financial platform for small and medium-sized businesses to transact and do business. It operates through the Israel, United States, and All Other Countries geographical segments. The company was founded in 2005 and is headquartered in New York, NY.

Payoneer Global Inc

Payoneer is trending as investors weigh strong profitability and double-digit core growth against conservative full-year guidance that has triggered recent market volatility. The community remains focused on the company's valuation gap compared to fintech peers, with ongoing discussions centered on potential buyout interest, stock buyback execution, and long-term expansion in high-growth B2B and merchant services.

Open Text Corp. engages in the design, development, marketing and sales of enterprise information management software and solutions. It includes customer experience management (CEM), digital process automation, business network, and enterprise content management, discovery, security, and artificial intelligence (AI) and analytics solutions. It also offers consulting, managed, and learning services. The company was founded on June 26, 1991 and is headquartered in Waterloo, Canada.

Open Text Corp

Open Text is garnering attention as investors and the community weigh its consistent cloud-driven growth and dividend yield against concerns about its recent stock price performance and long-term relevance. While some are optimistic about the firm's strategic focus on AI and cloud-based information management, others remain skeptical, focusing on the potential for market saturation and the ongoing challenge of sustaining growth in a competitive software environment.

Air Canada engages in the provision of airline transportation services. Its services cover full-service airline, scheduled passenger and cargo services, serving more than two hundred airports on six continents. It operates through the following geographical segments: Canada, U.S. Transborder, Atlantic, Pacific, and Other. The company was founded on April 11, 1936 and is headquartered in Saint-Laurent, Canada.

Air Canada Inc. - Ordinary Shares (Voting and Variable Voting)

Air Canada Inc.

Air Canada is trending as investors react to a new tentative collective agreement with Unifor that aims to stabilize operations and long-term labor relations. The community remains deeply divided, with bulls highlighting strong international booking demand and ticket pricing power, while skeptics point to the stock's historical inability to sustain rallies and ongoing concerns regarding fuel cost sensitivity and geopolitical risks.

Hewlett Packard Enterprise Co. is a global edge-to-cloud company, which engages in the provision of information technology, technology and enterprise products, solutions, and services. It operates through the following segments: Server, Hybrid Cloud, Intelligent Edge, Financial Services, and Corporate Investments and Other. The Server segment consists of general-purpose servers for multi-workload computing and workload-optimized servers to deliver the performance and value for demanding applications, and integrated systems comprised of software and hardware designed to address high-performance computing and supercomputing, artificial intelligence, data analytics, and transaction processing workloads for government and commercial customers globally. The Hybrid Cloud segment is involved in a variety of cloud-native and hybrid solutions across storage, private cloud, and the infrastructure software-as-a-service space. The Intelligent Edge segment offers wired and wireless local area networks, campus, branch, and data center switching, software-defined wide-area-networks, private and public cellular network software, network security, and associated services that enable secure connectivity for businesses of any size. The Financial Services segment provides investment solutions, such as leasing, financing, IT consumption, utility programs, and asset management services for customers that facilitate technology deployment models and the acquisition of complete IT solutions, including hardware, software, and services from Hewlett Packard Enterprise and others. The Corporate Investments and Other segment includes the Advisory and Professional Services business, which primarily offers consultative-led services, HPE and partner technology expertise and advice, implementation services, as well as complex solution engagement capabilities, the Communications and Media Solutions business, which primarily offers software and related services to the telecommunications industry, and Hewlett Packard Labs, which is responsible for research and development. The company was founded by William R. Hewlett and David Packard on July 2, 1939 and is headquartered in Spring, TX.

Hewlett Packard Enterprise Co

Hewlett Packard Enterprise is trending as the community debates its $931 million defense contract, balancing optimism for structural growth against concerns regarding margin pressures and the integration of Juniper Networks. Traders are closely monitoring the stock ahead of upcoming quarterly results, with active discussions focusing on its AI infrastructure backlog and its competitive standing against server peers like Dell and Super Micro.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Wall Street Analysts See a 120.59% Upside in Immix Biopharma (IMMX): Can the Stock Really Move This High?

The consensus price target hints at a 120.6% upside potential for Immix Biopharma (IMMX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

What's Going On With Immix Biopharma Stock Thursday?

Immix Biopharma (IMMX) prices $150M public offering to fund its NXC-201 cell therapy into mid-2028. Read the details.read more...

The Biotech Repricing Wave May Be Starting as Capital Pours into High-Impact Oncology Platforms

Biotech investors are once again rotating aggressively into clinical-stage growth stories as a fresh wave of capital raises, pipeline expansions, analyst initiations, and oncology breakthroughs reshapes momentum across the sector. $NTHI, $IMMX, $RLAY, $AKTX, $LIMN

Immix Biopharma (NASDAQ:IMMX) Trading Down 4.6%  - Time to Sell?

Immix Biopharma (NASDAQ:IMMX) Shares Down 4.6% - Time to Sell...

Immix Biopharma (NASDAQ:IMMX) Trading 12% Higher - Should You Buy?

Immix Biopharma (NASDAQ:IMMX) Stock Price Up 12% - Still a Buy...

Immix Biopharma, Inc. (NASDAQ:IMMX) Receives Average Rating of "Moderate Buy" from Brokerages

Immix Biopharma, Inc. (NASDAQ:IMMX - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the six brokerages that are currently covering the stock, MarketBeat reports. One...

Immix Biopharma (NASDAQ:IMMX) Stock Price Expected to Rise, Mizuho Analyst Says

Mizuho raised their target price on shares of Immix Biopharma from $14.00 to $15.00 and gave the company an "outperform" rating in a research note on Monday...

Immix Biopharma (NASDAQ:IMMX) Issues Quarterly Earnings Results

Immix Biopharma (NASDAQ:IMMX - Get Free Report) announced its quarterly earnings results on Wednesday. The company reported ($0.28) earnings per share for the quarter, missing analysts' consensus...

Citizens Jmp Reaffirms Market Outperform Rating for Immix Biopharma (NASDAQ:IMMX)

Citizens Jmp restated a "market outperform" rating and set a $23.00 price target on shares of Immix Biopharma in a research report on Friday...

Immix Biopharma (NASDAQ:IMMX) Given New $15.00 Price Target at HC Wainwright

HC Wainwright lifted their price objective on shares of Immix Biopharma from $12.00 to $15.00 and gave the stock a "buy" rating in a research note on Friday...

Immix Biopharma, Inc. operates as a biopharmaceutical company that engages in the development of therapies for cancer and inflammatory diseases. The company was founded by Ilya Rachman, Sean Senn, and Vladimir Torchilin in 2012 and is headquartered in Los Angeles, CA.

IMMX
Immix Biopharma Inc

Feed

News

Sentiment

Fundamentals

Info

Historical Earnings

Compact View

Latest IMMX News

IMMXImmix Biopharma Inc